Careers  |  Sign In  |  Register

Latest in Surgery

Reuters Health • The Doctor's Channel Daily Newscast

No benefit adding cetuximab to chemo after colon cancer resection

NEW YORK (Reuters Health) – Disease-free survival is not improved after resection of stage III colon cancer when cetuximab is added to chemotherapy with leucovorin, fluorouracil, and oxaliplatin (FOLFOX), according to study findings published in the Journal of the American Medical Association for April...

Reuters Health • The Doctor's Channel Daily Newscast

Adjuvant imatinib for three years advisable after GI stromal tumor resection

NEW YORK (Reuters Health) – In a European study, patients at high risk of recurrent gastrointestinal stromal tumor (GIST) who received imatinib (Gleevec; Novartis) for three years after surgery lived longer free of recurrence than their peers who took the drug for only one year following surgery. The...

Reuters Health • The Doctor's Channel Daily Newscast

Substernal goiter may be an under-recognized cause of OSA

NEW YORK (Reuters Health) – Goiter should be considered in the differential diagnosis of positional dyspnea, even in patients without obvious thyroid enlargement, according to a new retrospective analysis published online March 19 in the Archives of Surgery. “People are more symptomatic from thyroid...